AVROBIO, Inc. stock is down -17.76% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 November’s closed higher than October.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies. Its product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.